There are a lot of rational reasons to agree that 2025-2026 should be momentous for both patients and shareholders. The accumulation of data from 5 separate clinical trials sets the stage for Xanamia Part B with interim results in Q3. We have a PET study showing the drug gets into the brain. We have Xanahes and Xanamia Part A in healthy volunteers. We have the biomarker study of Xanadu patients with elevated PTau showing clear superiority over placebo but in a small sample size. And we now have XanaCIDD showing undeniable clinical activity in patients with MDD. But the brain is complex and has confounded numerous trials over decades. Highly skilled and experienced researchers and neurologists passionately disagree about the causes and treatments of Alzheimers. We cannot take anything for granted. But the science supporting emestedastat is compelling, the data so far largely supports the hypothesis and there is strong rationale to believe in the effectiveness of this molecule. The executive team is first class in my opinion. To those who insist on miracles, go and see a movie - you will find it more satisfying. This is high risk for high return and the brain is a dangerous adversary for those looking for guarantees.
ACW Price at posting:
2.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)